Table 1.
Baseline demographic, disease, and treatment characteristic summary: percentages are calculated based on the number of nonmissing values
| Variable | Nonmetastatic patients (n = 100) | Metastatic patients (n = 30) | All chest wall patients (n = 130) |
|---|---|---|---|
| Study | |||
| IRS-I | 20 (20%) | 4 (13%) | 24 (18%) |
| IRS-II | 28 (28%) | 14 (47%) | 42 (32%) |
| IRS-III | 27 (27%) | 5 (17%) | 32 (25%) |
| IRS-IV | 19 (19%) | 2 (7%) | 21 (16%) |
| IRS-IVP | 6 (6%) | 5 (17%) | 11 (8%) |
| XRT given | |||
| Yes | 67 (74%) | 23 (77%) | 90 (74%) |
| Sex | |||
| Female | 41 (41%) | 21 (70%) | 62 (48%) |
| Histologic finding | |||
| Alveolar | 34 (34%) | 14 (47%) | 48 (37%) |
| Embryonal/spindle cell | 27 (27%) | 8 (27%) | 35 (27%) |
| Rhabdo NOS | 1 (1%) | 1 (1%) | |
| Undifferentiated | 20 (20%) | 4 (13%) | 24 (18%) |
| Sarcoma, not classifiable | 8 (8%) | 2 (7%) | 10 (8%) |
| Other | 10 (10%) | 2 (7%) | 12 (9%) |
| Age (y) | |||
| <1 | 6 (6%) | 2 (7%) | 8 (6%) |
| 1–9 | 53 (53%) | 11 (37%) | 64 (49%) |
| 10+ | 41 (41%) | 17 (57%) | 58 (45%) |
| Stage | |||
| 1 | |||
| 2 | 14 (31%) | 14 (19%) | |
| 3 | 30 (67%) | 30 (42%) | |
| 4 | 1 (2%) | 27 (100%) | 28 (39%) |
| Group | |||
| I A | 19 (19%) | 19 (15%) | |
| I B | 4 (4%) | 4 (3%) | |
| II A | 30 (30%) | 30 (23%) | |
| II B | 3 (3%) | 3 (2%) | |
| III | 44 (44%) | 44 (34%) | |
| IV | 30 (100%) | 30 (23%) | |
| Size | |||
| ≤5 cm | 15 (35%) | 1 (13%) | 16 (31%) |
| T-Stage | |||
| T-1 | 23 (52%) | 23 (43%) | |
| T-2 | 21 (48%) | 9 (100%) | 30 (57%) |
| Nodal status | |||
| N-0 | 33 (72%) | 6 (67%) | 39 (71%) |
| N-1 | 6 (13%) | 3 (33%) | 9 (16%) |
| N-X | 7 (15%) | 7 (13%) | |
XRT, radiation therapy.